C4 Therapeutics, Inc. (CCCC) Spending and interest coverage
- R&D / revenue · 12 months: Value 285.53%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 40.83%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 285.53% | Research and development expense / revenue. Period ending 2026-06-30. $100.05M ÷ $35.04M × 100 ≈ 285.53% |
| Stock-based compensation / revenue · 12 months | 40.83% | Share-based compensation / revenue. Period ending 2026-06-30. $14.31M ÷ $35.04M × 100 ≈ 40.83% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 100.05M USD | Research and Development Expense |
| Revenue | 35.04M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.31M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -111.77M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $100.05M | $35.04M | $14.31M | $-111.77M | (m) | 285.53% | 40.83% | (m) | (m) |
| 2026-03-31 | $101.77M | $34.86M | $16.26M | $-113.84M | (m) | 291.94% | 46.65% | (m) | (m) |
| 2025-12-31 | $104.24M | $35.95M | $19.10M | $-115.22M | (m) | 289.98% | 53.13% | (m) | (m) |
| 2025-09-30 | $111.77M | $30.11M | $23.33M | $-129.79M | (m) | 371.23% | 77.48% | (m) | (m) |
| 2025-06-30 | $117.62M | $34.24M | $27.57M | $-123.62M | (m) | 343.52% | 80.51% | (m) | (m) |
| 2025-03-31 | $115.18M | $39.78M | $28.95M | $-116.56M | (m) | 289.51% | 72.78% | (m) | (m) |
| 2024-12-31 | $110.64M | $35.58M | $29.66M | $-119.61M | (m) | 310.92% | 83.36% | (m) | (m) |
| 2024-09-30 | $108.52M | $33.67M | $27.79M | $-119.33M | (m) | 322.31% | 82.53% | (m) | (m) |
| 2024-06-30 | $105.02M | $29.38M | $27.16M | $-118.90M | (m) | 357.49% | 92.43% | (m) | (m) |
| 2024-03-31 | $111.20M | $20.04M | $27.20M | $-135.02M | (m) | 554.99% | 135.75% | (m) | (m) |
| 2023-12-31 | $117.71M | $20.76M | $27.23M | $-139.03M | (m) | 567.09% | 131.22% | (m) | (m) |
| 2023-09-30 | $117.97M | $20.35M | $27.80M | $-139.90M | (m) | 579.72% | 136.59% | (m) | (m) |
| 2023-06-30 | $119.28M | $16.03M | $25.61M | $-144.58M | (m) | 744.08% | 159.73% | (m) | (m) |
| 2023-03-31 | $120.68M | $27.20M | $27.33M | $-134.39M | (m) | 443.66% | 100.47% | (m) | (m) |
| 2022-12-31 | $117.84M | $31.10M | $30.02M | $-129.53M | (m) | 378.96% | 96.53% | (m) | (m) |
| 2022-09-30 | $113.74M | (m) | $29.45M | $-106.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $108.38M | (m) | $29.52M | $-98.26M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $100.34M | (m) | $26.61M | $-92.99M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $94.67M | (m) | $21.51M | $-82.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $88.55M | (m) | $17.88M | $-85.78M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $88.18M | (m) | $12.23M | $-79.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $82.65M | (m) | $7.16M | $-68.62M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $78.44M | (m) | $3.43M | $-60.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $48.06M | (m) | $1.64M | $-35.45M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |